Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07733349 UX-DA003 Parkinson Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07733349 clinical trial report covering UX-DA003, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07734649 RSV/hMPV mRNA Vaccine (Sanofi) Human Metapneumovirus Infection Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07734649 clinical trial report covering RSV/hMPV mRNA Vaccine (Sanofi), Phase 1/2, endpoints, sponsor, geography, readout timing and development white s
Latest Hotspot
8 min read
NCT07735104 QLS2319 Cachexia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07735104 clinical trial report covering QLS2319, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07734077 Momelotinib Dihydrochloride Post-essential thrombocythemia myelofibrosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07734077 clinical trial report covering Momelotinib Dihydrochloride, Phase 1/2, endpoints, sponsor, geography, readout timing and development white spac
Latest Hotspot
8 min read
NCT07735533 UB-VV400 High grade B-cell lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07735533 clinical trial report covering UB-VV400, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07736937 TUB-040 Ovarian Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07736937 clinical trial report covering TUB-040, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07737600 Bevacizumab Advanced Colorectal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07737600 clinical trial report covering Bevacizumab, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07737678 BDDE cross-linked sodium hyaluronate gel Intrabony periodontal defect Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07737678 clinical trial report covering BDDE cross-linked sodium hyaluronate gel, Phase 1/2, endpoints, sponsor, geography, readout timing and developme
Latest Hotspot
8 min read
NCT07736612 Adebrelimab Pancreatic adenocarcinoma metastatic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07736612 clinical trial report covering Adebrelimab, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262952 Bevacizumab biosimilar (Tot Biopharm) Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
CTR20262952 clinical trial report covering Bevacizumab biosimilar (Tot Biopharm), Phase 1/2, endpoints, sponsor, geography, readout timing and development
Latest Hotspot
8 min read
CTR20262930 OTR-8100 Advanced cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
CTR20262930 clinical trial report covering OTR-8100, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07739511 Trastuzumab HER2 Positive Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07739511 clinical trial report covering Trastuzumab, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.